These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1081 related articles for article (PubMed ID: 31870811)

  • 1. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.
    Sanchez A; Furberg H; Kuo F; Vuong L; Ged Y; Patil S; Ostrovnaya I; Petruzella S; Reising A; Patel P; Mano R; Coleman J; Russo P; Liu CH; Dannenberg AJ; Chan TA; Motzer R; Voss MH; Hakimi AA
    Lancet Oncol; 2020 Feb; 21(2):283-293. PubMed ID: 31870811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma.
    Labadie BW; Liu P; Bao R; Crist M; Fernandes R; Ferreira L; Graupner S; Poklepovic AS; Duran I; Maleki Vareki S; Balar AV; Luke JJ
    J Transl Med; 2019 Nov; 17(1):386. PubMed ID: 31767020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
    McQuade JL; Daniel CR; Hess KR; Mak C; Wang DY; Rai RR; Park JJ; Haydu LE; Spencer C; Wongchenko M; Lane S; Lee DY; Kaper M; McKean M; Beckermann KE; Rubinstein SM; Rooney I; Musib L; Budha N; Hsu J; Nowicki TS; Avila A; Haas T; Puligandla M; Lee S; Fang S; Wargo JA; Gershenwald JE; Lee JE; Hwu P; Chapman PB; Sosman JA; Schadendorf D; Grob JJ; Flaherty KT; Walker D; Yan Y; McKenna E; Legos JJ; Carlino MS; Ribas A; Kirkwood JM; Long GV; Johnson DB; Menzies AM; Davies MA
    Lancet Oncol; 2018 Mar; 19(3):310-322. PubMed ID: 29449192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma.
    Hakimi AA; Furberg H; Zabor EC; Jacobsen A; Schultz N; Ciriello G; Mikklineni N; Fiegoli B; Kim PH; Voss MH; Shen H; Laird PW; Sander C; Reuter VE; Motzer RJ; Hsieh JJ; Russo P
    J Natl Cancer Inst; 2013 Dec; 105(24):1862-70. PubMed ID: 24285872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management.
    Maruschke M; Reuter D; Koczan D; Hakenberg OW; Thiesen HJ
    BJU Int; 2011 Jul; 108(2 Pt 2):E29-35. PubMed ID: 21435154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma.
    Tripathi A; Lin E; Xie W; Flaifel A; Steinharter JA; Stern Gatof EN; Bouchard G; Fleischer JH; Martinez-Chanza N; Gray C; Mantia C; Thompson L; Wei XX; Giannakis M; McGregor BA; Choueiri TK; Agarwal N; McDermott DF; Signoretti S; Harshman LC
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33177176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.
    Kapur P; Peña-Llopis S; Christie A; Zhrebker L; Pavía-Jiménez A; Rathmell WK; Xie XJ; Brugarolas J
    Lancet Oncol; 2013 Feb; 14(2):159-167. PubMed ID: 23333114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment-Analyses from the German clinical RCC-Registry.
    Goebell PJ; Müller L; Hübner A; Harich HD; Boller E; Koska M; Jänicke M; Marschner N;
    Urol Oncol; 2018 Oct; 36(10):470.e1-470.e9. PubMed ID: 30131294
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Klümper N; Ralser DJ; Zarbl R; Schlack K; Schrader AJ; Rehlinghaus M; Hoffmann MJ; Niegisch G; Uhlig A; Trojan L; Steinestel J; Steinestel K; Wirtz RM; Sikic D; Eckstein M; Kristiansen G; Toma M; Hölzel M; Ritter M; Strieth S; Ellinger J; Dietrich D
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy.
    DiNatale RG; Xie W; Becerra MF; Silagy AW; Attalla K; Sanchez A; Mano R; Marcon J; Blum KA; Benfante NE; Voss MH; Motzer RJ; Coleman J; Choueiri TK; Reznik E; Russo P; Heng DYC; Hakimi AA
    Eur Urol Oncol; 2020 Feb; 3(1):47-56. PubMed ID: 31735646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commentary on "Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation." Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX. Lancet Oncol 2013; 14(2):159-67. [Epub 2013 Jan 16]. doi: 10.1016/S1470-2045(12)70584-3.
    Boorjian S
    Urol Oncol; 2014 Aug; 32(6):934-5. PubMed ID: 25087671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma.
    Parker AS; Lohse CM; Cheville JC; Thiel DD; Leibovich BC; Blute ML
    Urology; 2006 Oct; 68(4):741-6. PubMed ID: 17070345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel prognostic model based on immunogenomics for clear cell renal cell carcinoma.
    Wu Z; Shen Y; Fan D; Liu J; Chen D; Wang K; Xu X
    Int Immunopharmacol; 2021 Jan; 90():107119. PubMed ID: 33243605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lifetime Body Weight Trajectories and Risk of Renal Cell Cancer: A Large U.S. Prospective Cohort Study.
    Deng Z; Hajihosseini M; Moore JX; Khan S; Graff RE; Bondy ML; Chung BI; Langston ME
    Cancer Epidemiol Biomarkers Prev; 2023 Nov; 32(11):1651-1659. PubMed ID: 37624040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study.
    Zauderer MG; Martin A; Egger J; Rizvi H; Offin M; Rimner A; Adusumilli PS; Rusch VW; Kris MG; Sauter JL; Ladanyi M; Shen R
    Lancet Digit Health; 2021 Sep; 3(9):e565-e576. PubMed ID: 34332931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
    Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
    Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of body mass index on the long-term survival of patients with renal cell carcinoma after tumour nephrectomy.
    Haferkamp A; Pritsch M; Bedke J; Wagener N; Pfitzenmaier J; Buse S; Hohenfellner M
    BJU Int; 2008 May; 101(10):1243-6. PubMed ID: 18261150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis.
    Choi Y; Park B; Jeong BC; Seo SI; Jeon SS; Choi HY; Adami HO; Lee JE; Lee HM
    Int J Cancer; 2013 Feb; 132(3):625-34. PubMed ID: 22610826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.